Timing: BPC-157 can be injected near the injury site
Its mechanism of action includes stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways
No peer-reviewed clinical studies, pharmacokinetic interaction data, or regulatory guidance exist on the combined use of AOD 9604 and retatrutide
Data availability Access to NESDA data used in the present study can be obtained by submitting a research proposal
Compounding pharmacies are regulated by state boards of pharmacy and applicable federal requirements
Wang Z, Bergeron N, Levison BS, Li XS, Chiu S, Jia X, Koeth RA, Li L, Wu Y, Tang WHW, et al